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What’s already known about this topic?  
 Reported prevalences of depression in patients with systemic lupus erythematosus range 
widely, while the prevalence of depression in cutaneous lupus erythematosus remains 
severely understudied. 
What does this study add?  
 In this nationwide cohort study patients with cutaneous or systemic lupus erythematosus 
had a 2-fold increased risk of depression compared with the general population in Denmark. 
 The risk of self-harm and death from suicide were not significantly increased in patients with 
lupus erythematosus. 
 
Summary 
Background Reported prevalences of depression in patients with systemic lupus erythematosus 
(SLE) range widely, while the prevalence of depression in cutaneous lupus erythematosus (CLE) 
remains severely understudied. 
 
Objectives To examine whether patients with SLE or CLE have increased risk of depression. 
 
Methods In this nationwide observational cohort study, we included patients ≥ 18 years with a first-
time diagnosis of SLE or CLE between 2000–2015 identified in the Danish National Patient Register 
matched with general population in a 1:10 ratio. After linkage to national Danish health registers of 
primary and secondary care, analyses of risk for depression and antidepressant use were performed 
in Cox regression models adjusted for age, sex, socio-economic status, smoking, alcohol abuse, prior 
depression, and prior antidepressant use. 
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Results A total of 3,489 patients with lupus erythematosus were followed for 23,373 person-years. 
The adjusted hazard ratios (HRs) of depression were 2.07 (95% CI, 1.55–2.75) and 2.22 (95% CI, 
1.77–2.77) for patients with CLE and SLE, respectively, compared with general population; for 
hospitalization due to depression at department of Psychiatry, HRs were 2.63 (95% CI, 0.80–8.67) 
and 3.52 (95% CI, 1.53–8.11) for patients with CLE and SLE, respectively. The adjusted HRs of 
antidepressant use were 1.47 (95% CI, 1.34–1.63) and 1.70 (95% CI, 1.58–1.83) for patients with CLE 
and SLE.  
 
Conclusions The risk of depression was significantly increased in patients with SLE and CLE. 
Awareness of increased risk of depression in patients with SLE and CLE might be warranted. 
 
Introduction 
Lupus erythematosus (LE) is a chronic autoimmune disease which may present in a systemic or a 
localized cutaneous form. As apparent by the name systemic lupus erythematosus (SLE) may not 
only involve the skin but also internal organs such as lungs, heart, and kidneys, whereas cutaneous 
lupus erythematosus (CLE) is mainly restricted to the skin1.  
 
Quality of life is considerably impaired in patients with SLE as well as in patients with CLE2,3. In 
patients with SLE, prevalence of depression ranges from 2–92% depending on factors such as study 
design and diagnostic criteria4, while the prevalence of depression in CLE remains severely 
understudied. Likewise, data on the incidence of depression in adults after being diagnosed with CLE 
or SLE remain scarce.  
 
Since depression is associated with morbidity, decreased quality of life, and increased mortality for 
the individual patient5,6 as well as a high economic burden on society7, it is important to investigate 
whether patients with CLE or SLE have an increased risk of depression. We therefore investigated 
the association between LE and risk of depression in a nationwide cohort of the Danish population.  
 
 
Materials and methods  
Study design 
A nationwide longitudinal cohort study was performed to examine whether patients with SLE or CLE 
have increased risk of depression.  
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Data sources  
To conduct the current study nationwide Danish health registers were used. In Denmark, each 
resident is given a unique and lifelong Civil Personal Register (CPR) number at birth or upon 
immigration to Denmark. This CPR number makes it possible to cross-link between a wide range of 
national health registers.  
 
From the Danish Civil Registration System, information on date of birth, sex, migration, ethnicity, 
and vital status were obtained8. Diagnoses were acquired from the Danish National Patient Register 
(DNPR). The Danish National Health Service Register (NHSR) contains information from the primary 
care and is a part of the tax-funded public healthcare system9. Data were also obtained from the 
Register of Medicinal Products Statistics that contains information on all pharmacy-dispensed and 
redeemed prescription since 199510. The data regarding suicides were obtained from the Register of 
Causes of Death11. Finally, information on socio-economic status was calculated based on data from 
the Income Statistics Register12. See Supplementary File for elaborating description of data sources.   
 
Study population 
The source population comprised all residents in Denmark ≥ 18 years from 2000–2015. People < 18 
years were included the subsequent day of their 18th birthday.  
 
We identified all patients with a first-time diagnosis of CLE or SLE, either as primary or 
supplementary diagnosis (Supplementary Table I). Patients with a diagnosis of CLE or SLE before 
baseline were excluded. The baseline or index date for CLE or SLE was the date of the first diagnosis, 
and each case was matched on age, sex, and index date in a 1:10 ratio with individuals from the 
general population serving as reference group. That the reference group was matched on the index 
data meant that, i.e. patients in the reference population had to be alive, resident in the source 
population, and at risk of developing SLE or CLE at the date of the SLE/CLE diagnosis for the 
corresponding case. The index date for the matched population was the index date for the 
corresponding cases. The study population was followed from 1 January 2000 until 31 December 
2015, emigration, death, or the occurrence of an endpoint, whichever occurred first. Patients were 
matched with a reference population on age and sex. 
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Covariates 
A proxy for smoking was assessed using data on drugs prescribed for smoking cessation, diagnoses 
of smoking, tobacco use, chronic obstructive pulmonary disease, lung cancer, or treatments and/or 
therapeutic interventions aimed at smoking cessation13.  
 
Alcohol abuse was assessed by diagnoses of alcohol abuse or conditions strongly related to alcohol 
abuse, pharmacological treatment with drugs used for alcohol dependence, and treatment 
interventions for alcohol dependence14.  
 
Socio-economic status was defined by the average household income in the 5 years preceding index 
and was divided into age-standardized quintiles.  
 
Baseline depression was defined as a diagnosis of depression up to 5 years prior to index. 
 
Outcomes 
The primary study endpoint was depression, defined by either a diagnosis of depression recorded in 
the DNPR (ICD-10 codes F32 or F33) or depression registered by psychologists or GPs in the NHSR 
(Supplementary Table I). At the GP, the registration was the use of Hamilton Rating Scale for 
Depression, which is a test used to assess the severity of the depression. At the psychologist, the 
registration was a consultation due to depression.  
 
The secondary endpoint was a claimed prescription for antidepressants. 
 
Statistical analysis 
Continuous variables were presented as mean with standard deviation if normally distributed or as 
median with interquartile range if distribution was skewed, and frequencies with percentages for 
categorical data.  
 
Incidence rates (IRs) of depression and antidepressant use were determined for CLE, SLE, and 
general population and expressed as the number of events per 1,000 person-years (PY). Analyses of 
depression risk were performed in Cox regression models using calendar time as time scale and 
adjusted for sex, age, smoking, alcohol abuse, socio-economic status, previous depression, and prior 
antidepressant use. The variable, ethnicity, was not significant in univariate analysis and thus not 
included in the adjusted Cox regression model. Smoking, alcohol abuse, sex, previous depression, 
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and prior antidepressant use were all handled as binary variables in the analysis, whereas age was 
handled as a continuous variable, and socio-economic status as a categorical variable. Smoking, 
alcohol abuse, and LE status were included as time-dependent variables. LE status as time-
dependent variable made it possible to change status from CLE to SLE but not the opposite way. 
Model assumptions, including the proportional hazards assumption was tested and found to be 
valid.  
 
Due to clinical relevance, we performed subgroup analyses by sex, age (< 50 years, ≥ 50 years at LE 
diagnosis), and severe depression, which was defined as patients hospitalized due to depression at a 
hospital in general or at a department of Psychiatry. 
 
We considered a 2-sided p-value < 0.05 as statistically significant. Data management and statistical 
analyses were performed with the use of SAS software version 9.4 (SAS Institute, Cary, NC, USA) and 
Stata/MP version 14 (StataCorp, College Station, TX, USA).  
 
Sensitivity analyses 
First, we limited our inclusion to patients with a CLE or SLE diagnosis made by a rheumatologist, 
dermatologist or nephrologist to be surer of an accurate diagnosis. Second, to increase the validity 
of the definition of SLE we identified patients with SLE in two different ways; in one sensitivity 
analysis by using a previous validated algorithm for SLE with a positive predictive value (PPV) of 
89%15, and in another by only including patients with SLE on systemic therapies as methotrexate, 
hydroxychloroquine and systemic corticosteroids during follow-up. 
 
Furthermore, we made a sensitivity analysis excluding patients diagnosed with depression within 3 
months of their first LE diagnosis to give an impression if depression is a neuropsychiatric 
manifestation at time of LE or if depression is more prominent as a long-term outcome of LE. We 
also made an analysis where we excluded patients with prior depression (defined as 5 years before 
index) and prior antidepressant use (defined as 12 months before index), respectively. Additionally, 
we made a sensitivity analysis where we used LE status as a fixed variable. Patients with a diagnosis 
of both CLE and SLE were in a separate group. To address surveillance bias, we made a sensitivity 
analysis with an outcome which we did not believe was associated with LE. Our outcome was 
azithromycin, only azithromycin used for treatment of chlamydia (defined as 1 g of azithromycin in a 
single dose).           
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Results  
The study comprised 1,424 and 2,065 patients with CLE and SLE, respectively, matched with 34,890 
people from the general population in Denmark.  
 
Baseline characteristics of our study population are shown in Table 1. Overall, the median age for 
the first diagnosis of CLE or SLE at the hospital was approximately 51 years, however, patients with 
CLE being slightly older. More patients with LE smoked and had alcohol abuse compared with 
general population. 
 
 
The number of patients diagnosed with depression were 51, 89, and 653 in CLE, SLE, and general 
population, respectively. For depression, the follow-up time were 8,103, 15,270, and 253,547 PY for 
CLE, SLE, and general population, respectively, and the corresponding IRs were 6.29 (95% CI, 4.78–
8.28), 5.83 (95% CI, 4.74–7.17), and 2.58 (95% CI, 2.24–2.78) per 1,000 PY.  
 
The number of patients using antidepressants were 419, 790, and 8,224 in CLE, SLE, and general 
population, respectively. For antidepressant use, the follow-up time were 6,222, 11,074, and 
212,148 PY for CLE, SLE, and general population, respectively, and the corresponding IRs were 67.34 
(95% CI, 61.19–74.10), 71.34 (95% CI, 66.53–76.49), and 38.77 (95% CI, 37.94–39.61) per 1,000 PY.  
 
The period prevalence of depression corresponding to the study period was 3.6% in CLE, 3.4% in SLE, 
and 1.9% in the general population. The same pattern was observed for antidepressant use with 
period prevalences at 29.4%, 31.9%, and 23.6% in CLE, SLE, and in the general population, 
respectively.  
 
The use of hydroxychloroquine, methotrexate, systemic corticosteroids, and topical corticosteroids 
increased during follow up compared with baseline use (data not shown). However, only 50.1% and 
46.5% with CLE and SLE were treated with hydroxychloroquine during follow-up. 
 
Diagnoses of LE were associated with a significantly increased risk of depression. When adjusting for 
age, sex, smoking, alcohol abuse, socio-economic status, prior depression, and prior antidepressant 
use the HRs were 2.07 (95% CI, 1.55–2.75) and 2.22 (95% CI, 1.77–2.77) for patients with CLE and 
SLE, respectively (Table 2). 
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In a subgroup analysis, we found that patients with LE had an increased risk of severe depression 
compared with general population. For patients hospitalized due to depression at a hospital in 
general, the adjusted HRs were 2.90 (95% CI, 1.32–6.36) and 2.60 (95% CI, 1.32–5.06) for CLE and 
SLE, respectively. However, for patients hospitalized due to depression at a department of 
Psychiatry, the adjusted HRs were 2.63 (95% CI, 0.80–8.67) and 3.52 (95% CI, 1.53–8.11) for CLE and 
SLE, respectively (Supplementary Table II). 
 
Likewise, a significant association was seen between LE and antidepressant use. The adjusted HRs 
were 1.47 (95% CI, 1.34–1.63) and 1.70 (95% CI, 1.58–1.83) for patients with CLE and SLE, 
respectively (Table 2). HR for each covariate is presented in Supplementary Table III.  
 
The risk of depression was more pronounced in patients diagnosed with CLE or SLE < 50 years of age, 
especially for CLE. The adjusted HRs were 3.15 (95% CI, 2.02–4.92) and 2.28 (95% CI, 1.60–3.25) for 
patients with CLE and SLE < 50 years of age. For antidepressant use, the stratification in age did not 
alter the results significantly (Table 2).   
 
When stratifying for sex, the risk of depression or antidepressant use was significantly increased for 
both men and women. Men with CLE had a higher risk of depression than women. For 
antidepressant use, men with SLE had the highest risk (Supplementary Table IV). 
 
In a post hoc analysis, we found that death from suicide in general was seldom: only 3 completed 
suicides in the LE group and 43 completed suicides in the general population. The crude HR was 0.72 
(95% CI, 0.22–2.31) with p-value 0.576 and the adjusted HR was 0.55 (95% CI, 0.17–1.78) with p-
value 0.316 for completed suicides in patients with LE overall compared with general population. 
Likewise, self-harm were seldom with 3 and 31 cases in the LE group and general population.  The 
crude HR for self-harm in the LE group compared with general population was 1.00 (95% CI, 0.30–
3.26) with p-value 0.995 and the adjusted HR was 0.78 (95% CI, 0.24–2.58) with p-value 0.689. 
 
Sensitivity analyses 
We excluded patients with prior depression or prior antidepressant use from the analyses, which did 
not alter the clear trends in the study results (Supplementary Table V). Neither did the results alter 
worthily or significantly when we excluded patients diagnosed with depression within 3 months of 
their first LE diagnosis (data not shown).  When using a previously validated algorithm15 for defining 
patients with SLE, we found that the adjusted HRs were 2.04 (95% CI, 1.31–3.19) for depression and 
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1.56 (95% CI, 1.36–1.79) for antidepressant use (Supplementary Table VI). When we only included 
patients with SLE on systemic therapies as methotrexate, hydroxychloroquine and systemic 
corticosteroids during follow-up, we found that the statistical significance retained, the adjusted HRs 
were 2.48 (95% CI, 1.87-3.30) with a p-value <0.0001 for depression and 1.78 (95% CI, 1.63-1.94) 
with a p-value <0.0001 for antidepressant use. In the sensitivity analysis in which we only included 
patients with CLE or SLE diagnosed from a department of rheumatology, dermatology or nephrology, 
the results did not alter worthily (Supplementary Table VII). In the sensitivity analysis with CLE and 
SLE status as fixed variables the results were not significantly altered (Supplementary Table VIII). 
Finally, in the sensitivity analysis where the outcome was treatment with azithromycin for 
chlamydia, we found a crude HR of 1.31 (95% CI, 1.04–1.65) and an adjusted HR of 1.17 (95% CI, 
0.93–1.48) for patients with LE compared with general population.        
 
 
Discussion 
In this nationwide cohort study to examine the risk of depression in patients with LE, we found a 2-
fold increased risk of depression in patients with CLE or SLE compared with a matched group from 
the general population in Denmark. The risk for depression was of similar magnitude in the two 
groups, which indicates that the involvement of the skin has the same important impact as the 
systemic disease.  
 
The cause for the increased risk of depression in patients with SLE remains unclear. It is probably due 
to both direct and indirect consequences of the disease; a directly consequence as due to the 
systemic inflammation, and an indirectly consequence as due to the psychological burden of having 
and coping with a chronic disease16–20. Previous studies have shown that depression is associated 
with inflammation.  Proinflammatory cytokine levels such as interleukin (IL)-6, IL-1β, and tumor 
necrosis factor (TNF)-α are increased in patients with depression16,17. A study has shown that sera 
TNF-α levels are increased in patients with SLE and concomitant depressive symptoms19. However, a 
systematic review found that psychological factors were the most frequently reported cause for the 
association between SLE and depression18. The association between an autoimmune disease and a 
neuropsychiatric disease is also found in other autoimmune diseases beside LE, e.g. in patients with 
rheumatoid arthritis21,22.  
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In general, patients with dermatologic diseases have a reduced quality of life and have an increased 
prevalence of psychiatric morbidity including depression2. This is shown in previous studies where an 
association between depression and atopic dermatitis23, rosacea24, and psoriasis25 is found, which is 
in line with our findings regarding CLE and the increased risk of depression and antidepressant use.     
 
A systematic review and meta-analysis from 2017 with 59 studies reporting on a total of 10,828 
patients with SLE found that the prevalence of depression ranged from 2–92% between the studies 
4. This diversity is due to variation in the study design, sample size, country, and different definitions 
of depression. The meta-analysis showed that the pooled prevalence of depression in patients with 
SLE was 24% (95% CI, 16-31%) when using the Diagnostic and Statistical Manual of Mental Disorders 
and/or ICD diagnostic criteria4. This prevalence is higher than our period prevalence of depression, 
3.4%, and slightly lower than our period prevalence for antidepressant use, 31.9%. This indicate that 
the “true” prevalence of depression is somewhere between these prevalences. The reason for the 
discrepancy could be that we find too few patients with depression (see under Limitations and 
strengths) and only the severe cases with depression (patients seen at a hospital, seen by a 
psychologist or having a Hamilton Rating Scale for Depression test done at the GP). 
 
In contrast to SLE, the general knowledge regarding the association of patients with CLE and 
depression is sparse.  Only one previous study with a small sample size has examined the prevalence 
and odds ratio (OR)  of depression in patients with CLE26. This study showed a point prevalence of 9% 
for depression, a lifetime prevalence of 44%, and an OR 2.5 (95%, CI 1.2-5.0) for lifetime depression 
in patients with CLE26.   
  
The suicide risk is increased in patients with depression6. In our study the number of attempts and 
completed suicides was low and not increased in patients with LE compared with general 
population. Previous studies have described that suicidal ideation is common in SLE and, likewise, 
that the incidence rates of completed suicides and attempts are increased27,28.  
 
Limitations and strengths 
Several limitations need to be addressed. One limitation of the study is that some patients with CLE 
are followed by their private dermatologist or GP. Thus our results cannot be generalized to these 
patients who probably have a less severe disease burden and a lower risk of depression than 
patients followed in hospitals. Conversely, patients with SLE are typically followed at the hospital29.  
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Another limitation is the risk of not including all patients with depression. Firstly, far from all patients 
with depression are seen at a hospital. Secondly, there is a possibility that not all GP use the 
Hamilton Rating Scale for Depression to assess the severity of the depression, even though they are 
charged for it. This will underestimate the risk of depression in all groups. On the other hand, 
patients with LE receive increased medical scrutiny compared to general population, potentially 
giving rise to surveillance bias, i.e. increased contact with healthcare professionals increasing the 
likelihood of being diagnosed with depression. However, thirdly, fatigue and other symptoms of 
mood disorders are common in patients with SLE, thus patients’ complaints might be classified as 
symptom of SLE and not a depression. In the current study, we did not include the ICD-10 depression 
test or psychometric test for depression, as this would overestimate the risk of depression in each 
group, as not everyone who takes the test will be diagnosed with depression. The use of 
antidepressants as a surrogate marker of depression is not accurate as some patients treated with 
antidepressants are treated for anxiety, sleeping disorder or obsessive-compulsive disorder30. A 
study showed that the main indication in Denmark for treatment with antidepressant was 
depression followed by anxiety31.  
 
The strengths of our study are the nationwide covered registers with virtually complete follow-up, 
which was conducted in a country with free healthcare. Likewise, the long follow-up period and the 
large number of patients represent major strengths. To our knowledge, we are the first to examine 
the risk of depression in patients with SLE compared to a general population. We attempted to 
adjust for important confounders such as smoking and alcohol abuse by using proxies. However, the 
use of these proxies may result in residual confounding. Further, we made numerous sensitivity 
analyses, including a validated algorithm to identify patients with SLE, and none of them did alter the 
results significantly. Likewise, we made a sensitivity analysis with azithromycin as outcome where 
the magnitude of the HR suggests slight surveillance bias, however unlikely to fully explain our 
results. Due to the observational study design, we cannot conclude anything on causality, even 
though the sensitivity analysis excluding patients diagnosed with depression within 3 months of their 
first LE diagnosis gives the impression that depression is a long-term outcome of the LE disease, or at 
least it is less convincing that depression is due to a neuropsychiatric manifestation at time of LE 
diagnosis.  
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We found significantly increased risk of depression in patients with CLE and SLE compared with a 
matched group from the general population in Denmark. The risk for depression is of similar 
magnitude in both groups indicating that the involvement of the skin as well as the systemic 
involvement affects the overall risk of depression. Notably, rheumatologists and dermatologists 
should be aware of the increased risk of depression in patients with LE. 
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Table 1 Baseline characteristics of the study population             
           
   
Patients with lupus erythematosus*  
(n = 3,489) 
   
   
       CLE                                       
         (n = 1,424)  
                 SLE                                   
                 (n = 2,065)  
 General population      
                (n = 34,890) Characteristics       
Age (years), median (IQR) 54.3 (41.8, 66.2)  
 
48.9 (35.6, 61,8) 
 
51.1 (38.0, 63.8) 
Women, n (%) 
 
1,127 (79.1) 
 
1,660 (80.4) 
 
27,870 (79.9) 
Smoking, n (%) 
 
402 (28.2) 
 
504 (24.4) 
 
5,213 (14.9) 
Socio-economic status, n (%) 
            Lowest 
  
244 (17.1) 
 
400 (19.4) 
 
7,031 (20.2) 
    Below average 
 
372 (26.1) 
 
439 (21.3) 
 
6,865 (19.7) 
    Average 
  
309 (21.7) 
 
457 (22.1) 
 
6,910 (19.8) 
    Above average 
 
268 (18.8) 
 
385 (18.6) 
 
7,023 (20.1) 
    Highest 
  
231 (16.2) 
 
384 (18.6) 
 
7,061 (20.2) 
Ethnicity, n (%)a 
             Ethnic Danes 
 
1,331 (93.5) 
 
1,916 (92.8) 
 
32,856 (94.2) 
    Immigrants 
 
88 (6.2) 
 
138 (6.7) 
 
1,858 (5.3) 
    Descendants  
 
5 (0.4) 
 
11 (0.5) 
  
175 (0.5) 
Comorbidity, n (%) 
             Alcohol abuse 
 
114 (8.0) 
 
95 (4.6) 
 
1,299 (3.7) 
    Depressionb 
 
21 (1.5) 
 
37 (1.8) 
 
279 (0.8) 
Medication, n (%)c  
             Antidepressants 
 
36 (2.5) 
 
80 (3.9) 
 
565 (1.6) 
    Hydroxychloroquine 142 (10.0) 
 
114 (5.5) 
 
11 (0.03) 
    Methotrexate  
 
17 (1.2) 
 
62 (3.0) 
 
59 (0.2) 
    Systemic corticosteroids 124 (8.7) 
 
223 (10.8) 
 
436 (1.3) 
    Topical corticosteroids 153 (10.7) 
 
128 (6.2) 
 
733 (2.1) 
                      
* Lupus erythematosus status is in this baseline table indicated as first-time registration of CLE or SLE, which only are for 
descriptive purposes. In the analyses, LE status is used as a time-dependent variable. 
a Due to Denmark's Statistic, an immigrant is defined as a person not born in Denmark and none of the parents are Danish 
citizens or born in Denmark. Descendant is defined as a person born in Denmark, where none of the parents are Danish citizens 
or born in Denmark.  
b Baseline depression is 5 years prior to index. 
   
 
  
c Baseline medication is a claimed prescription up to 12 months prior to index. 
 
 
  
CLE, cutaneous lupus erythematosus; IQR, interquartile range; SLE, systemic lupus erythematosus.  
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Table 2 Crude and adjusted hazard ratios for depression and antidepressant use in patients with lupus erythematosus 
compared with the general population, below stratified for age (< 50 years and ≥ 50 years at diagnosis of lupus erythematosus) 
                Crude HR (95% CI) P-value   Adjusted HR* (95% CI) P-value 
Depression  
            CLE 
  
2.53 (1.90-3.37) <0.0001 
 
2.07 (1.55-2.75) <0.0001 
    SLE 
  
2.38 (1.90-2.97) <0.0001 
 
2.22 (1.77-2.77) <0.0001 
          Antidepressant use 
            CLE 
  
1.73 (1.56-1.90) <0.0001 
 
1.47 (1.34-1.63) <0.0001 
    SLE 
  
1.87 (1.74-2.02) <0.0001 
 
1.70 (1.58-1.83) <0.0001 
          
   
Age < 50 years 
 
  Age ≥ 50 years   
   
Adjusted HR* (95% CI) P-value   Adjusted HR* (95% CI) P-value 
Depression  
            CLE 
  
3.15 (2.02-4.92) <0.0001 
 
1.72 (1.18-2.51) 0.005 
    SLE 
  
2.28 (1.60-3.25) <0.0001 
 
2.12 (1.58-2.83) <0.0001 
          Antidepressant use 
            CLE 
  
1.62 (1.38-1.89) <0.0001 
 
1.42 (1.25-1.62) <0.0001 
    SLE 
  
1.65 (1.38-1.89) <0.0001 
 
1.73 (1.56-1.92) <0.0001 
         
  
a Defined by either a diagnosis of depression recorded in the Danish National Patient Register or depression registered by 
psychologists or general practitioners in the Danish National Health Service Register.  
CI, confidence interval; CLE, cutaneous lupus erythematosus; HR, Hazard Ratio; SLE, systemic lupus erythematosus. 
* Adjusted for age, sex, smoking, alcohol abuse, socio-economic status, prior depression, and prior antidepressant use. 
 
